Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Alzheimer’s group files FOIA request related to CMS decision on amyloid-targeting antibodies 

By Brian Buntz | April 15, 2022

USAgaistAlzheimer'sUsAgainstAlzheimer’s, a nonprofit organization committed to stopping Alzheimer’s disease, is hoping to get more information related to CMS’s national coverage determination related to coverage for Aduhelm (aducanumab) from Biogen (Nasdaq:BIIB) and other monoclonal antibodies targeting amyloid to treat Alzheimer’s disease.

The organization has filed a Freedom of Information Act (FOIA) request for information about the decision.

UsAgainstAlzheimer’s is seeking information describing the potentially harmful impact of refusing to cover such monoclonal antibodies outside of clinical trials.

CMS announced their national coverage determination for Aduhelm and other similar future monoclonal antibodies last week.

UsAgainstAlzheimer’s concluded that CMS has denied access to millions of people in the U.S. living with Alzheimer’s.

“The National Coverage Determination is historic – and not in a good way. CMS has covered every FDA-approved drug, but now there are two classes of patients within Medicare: people with Alzheimer’s and everyone else,” said UsAgainstAlzheimer’s chairman and co-founder George Vradenburg, in a press release.

“Patients deserve the same level of transparency from CMS that they get from the FDA, which is why we are demanding answers on how this decision was crafted and what it means for future treatments.”

Aduhelm earned Biogen just $3 million in 2021.


Filed Under: Biologics, Neurological Disease
Tagged With: Aduhelm, Alzheimer’s, Biogen, CMS, FOIA, Freedom of Information Act, UsAgainstAlzheimer’s
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

PolarityTE
How PolarityTE aims to help heal chronic wounds
Axogen
Axogen announces positive topline data from Phase 3 nerve graft study
Janssen
Janssen’s company group chairman dishes on growth strategy
AstraZeneca
Imfinzi with chemotherapy gets FDA priority review for locally advanced or metastatic biliary tract cancer

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50